MeiraGTx Holdings (MGTX) Other financing activities (2018 - 2025)

MeiraGTx Holdings' (MGTX) quarterly Other financing activities came in at $211000.0 in Q4 2025, up 1818.18% on a QoQ basis from $11000.0 in Q3 2025.

MeiraGTx Holdings (MGTX) Other financing activities (2018 - 2025) Analysis & Trends

MeiraGTx Holdings (MGTX) has 7 years of Other financing activities data on file, last reported at $211000.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $211000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $257000.0 (changed N/A YoY) and the FY2025 annual result came in at $257000.0, changed N/A from the prior year.
Other financing activities improved to $211000.0 in Q4 2025, from $11000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $3.0 million in Q2 2022 to a low of -$2.8 million in Q1 2022.
A 4-year average of $80500.0 and a median of $46500.0 in 2021 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 1254.34% in 2022, down 2067.38% in 2022.
Tracing MGTX's Other financing activities over 4 years: stood at $1.3 million in 2021, then sank by 96.99% to $39000.0 in 2022, then plunged by 3256.41% to -$1.2 million in 2023, then surged by 117.14% to $211000.0 in 2025.
The last three Other financing activities figures came in at $211000.0 (Q4 2025), $11000.0 (Q3 2025), and $31000.0 (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	MeiraGTx Holdings	1.10 Bn	1.03 Bn	-

Download Data